Publication:


abstract

the Adoptive transfer of tumor antigen-specific T cells recently achieved clinical efficacy for a fraction of melanoma patients refractory to other therapies. Unfortunately, the application of this strategy to the remaining melanoma and most other cancer patients is hampered by the difficulty to generate high-affinity tumor-reactive T cells. Two strategies are currently developed to extend the feasibility of this therapeutic approach: clinical grade tool production for MHC-peptide multimer-driven sorting of antigen-specific T cells from the endogenous peripheral T cell repertoire and de novo engineering of the missing repertoire by genetic transfer of cloned specific T cell receptor (TCR) into T cells. The expected multiplication of adoptive transfer treatments, by these strategies, and their careful evaluation should enable the cure of a number of otherwise compromised cancer patients and to gain insight into the characteristics of transferred T cells best fitted to eradicate tumor cells, in terms of antigen specificities, phenotype, and functions. In particular, identification of tumor-rejection antigens by this approach would improve the design and efficacy of all immunotherapeutic approaches.

Related Articles
Review Genetic engineering of T cell specificity for immunotherapy of cancer.
Hum Immunol. 2003
Review Genetic engineering of T cell specificity for immunotherapy of cancer.
Willemsen RA, Debets R, Chames P, Bolhuis RL. Hum Immunol. 2003 Jan; 64(1):56-68.
Genetic engineering with T cell receptors.
Adv Drug Deliv Rev. 2012
Genetic engineering with T cell receptors.
Zhang L, Morgan RA. Adv Drug Deliv Rev. 2012 Jun 1; 64(8):756-62. Epub 2011 Dec 9.
CD8 alpha coreceptor to improve TCR gene transfer to treat melanoma: down-regulation of tumor-specific production of IL-4, IL-5, and IL-10.
J Immunol. 2006
CD8 alpha coreceptor to improve TCR gene transfer to treat melanoma: down-regulation of tumor-specific production of IL-4, IL-5, and IL-10.
Willemsen RA, Sebestyén Z, Ronteltap C, Berrevoets C, Drexhage J, Debets R. J Immunol. 2006 Jul 15; 177(2):991-8.
T-cell receptor gene therapy targeting melanoma-associated antigen-A4 inhibits human tumor growth in non-obese diabetic/SCID/γcnull mice.
Cancer Sci. 2012
T-cell receptor gene therapy targeting melanoma-associated antigen-A4 inhibits human tumor growth in non-obese diabetic/SCID/γcnull mice.
Shirakura Y, Mizuno Y, Wang L, Imai N, Amaike C, Sato E, Ito M, Nukaya I, Mineno J, Takesako K, et al. Cancer Sci. 2012 Jan; 103(1):17-25. Epub 2011 Nov 8.
Review WT1-specific T cell receptor gene therapy: improving TCR function in transduced T cells.
Blood Cells Mol Dis. 2008
Review WT1-specific T cell receptor gene therapy: improving TCR function in transduced T cells.
Stauss HJ, Thomas S, Cesco-Gaspere M, Hart DP, Xue SA, Holler A, King J, Wright G, Perro M, Pospori C, et al. Blood Cells Mol Dis. 2008 Jan-Feb; 40(1):113-6. Epub 2007 Sep 12.